statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neutral SRF; target of Rs 2,100: Motilal Oswal

Motilal Oswal recommended accumulate rating on SRF with a target price of Rs 2,100 in its research report dated May 09, 2024.

Neutral Alembic Pharma; target of Rs 960: Motilal Oswal

Motilal Oswal recommended accumulate rating on Alembic Pharma with a target price of Rs 960 in its research report dated May 09, 2024.

Alembic Pharma gets tentative USFDA nod for breast cancer drug

The tentative approval by the US Food &amp; Drug Administration (USFDA) was for Ribociclib tablets of strength 200 mg, Alembic Pharmaceuticals said in a regulatory filing.

Alembic Pharma drops 2% on USFDA 4 observations for Gujarat facility

The US drug regulator had inspected Alembic Pharma's oncology formulations (injectable and oral solid) unit at Panelav in Gujarat from February 28 to March 8

Riding on Novo Nordisk’s semaglutide, India’s weight-loss market triples in size in 2 years

Semgalutide has almost 66 percent of the market share in the anti-obesity segment.

Experts list top 10 picks for next one month, despite a muted start in 2024

As the market advances, it is advisable to focus on risk management and have a selective approach while looking out for thematic movers amidst the ongoing sectoral rotation, Sameet Chavan said.

Alembic Pharmaceuticals Ltd. is a research and development pharmaceutical company, which engages in the research, development, manufacture, and market of generic and branded pharmaceutical products. The firm's businesses are Active Pharmaceutical Ingredients and Formulations. It focuses on the following therapeutic areas: Dermatology, Cardiology, Anti-Diabetic, Gastrology, Ophthalmology, Nephrology and Urology, Anti-Infective, Oncology, and cold and cough. The company was founded by Tribhuvandas Kalyandas Gajjar in 1907 and is headquartered in Vadodara, India.

Volume	477,497.00
52-Wk High	1,224.90
52-Wk Low	707.15

APLLTD.NSE Alembic Pharmaceuticals Ltd

About

Feed

News

Sentiment

Fundamentals